Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinical study. The Phase 2b study A Phase 2b, Open-label Study to Evaluat...

Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial

The latest update is out from Vortex Energy Corp. ( ($TSE:VRTX) ). Vortex Energy has released final results from an Ambient Noise Tomography survey...

Vortex Energy Finalizes 3D Tomography Study at Robinsons River Salt Project

Jefferies analyst Akash Tewari maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $633.00. According to TipRanks, Te...

Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jade Biosciences (JBIO), Silence Therapeutics (SLN) ...

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX)

Shares of American biotech company Vertex Pharmaceuticals ($VRTX) jumped about 7% on Monday after its top rival Sionna Therapeutics ($SION) reporte...

Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and MoonLake Immunothe...

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX)

Analysts fell to the sidelines weighing in on Vertex Pharmaceuticals (VRTX) and Travere Therapeutics (TVTX) with neutral ratings, indicating that t...

Wall Street Analysts Are Neutral on Top Healthcare Picks

Vortex Energy Corp. ( ($TSE:VRTX) ) just unveiled an announcement. Vortex Energy Corp. reported final results from a technical study by Lonquist Fi...

Vortex Energy Study Confirms Major Salt Structure and New Target at Robinsons River

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (O...

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB) wit...

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB)

Barclays analyst Eliana Merle maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $617.00. Merle covers the Healthcar...

Barclays Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Danaher (DHR), Vertex Pharmaceuticals (VRTX) and Add...

Analysts’ Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)

In a report released today, Louise Chen from Scotiabank assigned a Buy rating to Vertex Pharmaceuticals, with a price target of $558.00. Chen cover...

Vertex Pharmaceuticals (VRTX) Gets a Buy from Scotiabank

Wells Fargo analyst Mohit Bansal assigned a Buy rating to Vertex Pharmaceuticals today and set a price target of $550.00. According to TipRanks, Ba...

Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceu...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRTX	$547.59	-0.08%	766.92K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRTX	$547.59	-0.1%	766.92K
3
4
5
6

VRTX

Get Vertex Pharmaceuticals Incorporated Data in Excel

Get Vertex Pharmaceuticals Incorporated Data in Excel